top of page
Sachi Microbiome Therapeutics to Counter Challenges in Mental Health and Auto-Immune Diseases
The human body contains trillions of microorganisms, far outnumbering human cells, and plays a vital role in human health at various scales. Several recent studies have outlined how a combination of genetic, environmental, physiological and psychological stressors can induce gut-dysbiosis, which impacts a vital gut-immune-brain axis, leading to generation of Reactive Oxygen Species (ROS) that damages cellular molecules, increased inflammation leading to auto-immune diseases like Rheumatoid Arthritis (RA) and Inflammatory Bowel Diseases (IBD), and causes deficit of key neurotransmitters and neurotrophic factors, vital for healthy brain function, mood, and mental health. While restoring homeostasis can revert the disease progression, two primary microbiome-therapeutic modalities fecal-matter transplant (FMT), and live biotherapeutics (LBP) or “bugs-as-drugs” carry associated risks and have met with limited clinical success.
A key potential reason identified has been focus on microbiome composition without assessing their location and potential impact on bacterial metabolites that primarily mediate host-microbiome interactions. One alternative is identifying key biosynthetic pathways that leads to generation of these key metabolites, primarily using Biosynthetic Gene Clusters (BGCs), then regulate their expression through up- or down-regulation of key BGCs reversibly, to restore homeostasis. Sachi recently revealed that their proprietary discovery engine and molecules Nanoligomers™ were used to reversibly and programmably regulate BGC expression, leading to facile modulation of key BGCs leading to modulation of key host immune, neurotransmitters (e.g. serotonin, dopamine), and neurotrophic factors to address challenges in mental health and neuropathology.
Sachi is now planning to advance and translate lead molecules to demonstrate safety and human clinical efficacy, providing a new breakthrough approach in addressing mental health crises and auto-immune disease using Sachi’s revolutionary platform technology. Sachi plans to unveil the data and pre-clinical outcomes in the coming months to the broader drug-development community and pharmaceutical industry.
For Partnership Opportunities: Contact email@example.com
bottom of page